Targeting Helicobacter pylori in liver-impaired populations: a systematic review of efficacy and safety
Abstract
Liver impairment can alter the metabolic capacity of the organ significantly, potentially affecting the efficacy and safety of Helicobacter pylori (H. pylori) eradication regimens. Although this issue is highly significant, no standardized guidelines currently exist for H. pylori eradication therapy in patients with liver dysfunction. To bridge this gap, we systematically reviewed studies on the efficacy and safety of H. pylori eradication therapy in individuals with liver impairment. The systematic review included a search of PubMed, the Igaku Chuo Zasshi, and the Cochrane Library database to identify eligible randomized controlled trials (RCTs) and/or non-randomized controlled trials (NRCTs). Three RCTs and five NRCTs were included. Research on the effectiveness of H. pylori eradication treatment in patients with and without liver disease has produced inconsistent findings, with a study reporting higher eradication rates in the liver disease group, and others finding no significant difference, leaving no definitive consensus. Two studies reported eradication rates 80% in groups with liver impairment. Furthermore, even in cases of advanced liver impairment such as non-alcoholic steatohepatitis (NASH) or liver cirrhosis, eradication rates did not decline, and adverse events were either minimal or comparable with those observed in groups without liver impairment. H. pylori eradication therapy is applicable and safe for patients with liver disease; however, treatment…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.